Cargando…

Prevention of cognitive decline in subjective cognitive decline APOE ε4 carriers after EGCG and a multimodal intervention (PENSA): Study design

INTRODUCTION: Subjects exhibiting subjective cognitive decline (SCD) are at an increased risk for mild cognitive impairment and dementia. Given the delay between risk exposure and disease onset, SCD individuals are increasingly considered a good target population for cost‐effective lifestyle‐based A...

Descripción completa

Detalles Bibliográficos
Autores principales: Forcano, Laura, Fauria, Karine, Soldevila‐Domenech, Natalia, Minguillón, Carol, Lorenzo, Thais, Cuenca‐Royo, Aida, Menezes‐Cabral, Sofia, Pizarro, Nieves, Boronat, Anna, Molinuevo, José Luis, de la Torre, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012239/
https://www.ncbi.nlm.nih.gov/pubmed/33816762
http://dx.doi.org/10.1002/trc2.12155
_version_ 1783673335100473344
author Forcano, Laura
Fauria, Karine
Soldevila‐Domenech, Natalia
Minguillón, Carol
Lorenzo, Thais
Cuenca‐Royo, Aida
Menezes‐Cabral, Sofia
Pizarro, Nieves
Boronat, Anna
Molinuevo, José Luis
de la Torre, Rafael
author_facet Forcano, Laura
Fauria, Karine
Soldevila‐Domenech, Natalia
Minguillón, Carol
Lorenzo, Thais
Cuenca‐Royo, Aida
Menezes‐Cabral, Sofia
Pizarro, Nieves
Boronat, Anna
Molinuevo, José Luis
de la Torre, Rafael
author_sort Forcano, Laura
collection PubMed
description INTRODUCTION: Subjects exhibiting subjective cognitive decline (SCD) are at an increased risk for mild cognitive impairment and dementia. Given the delay between risk exposure and disease onset, SCD individuals are increasingly considered a good target population for cost‐effective lifestyle‐based Alzheimer's disease prevention trials. METHODS: The PENSA study is a randomized, double‐blind, controlled clinical trial that aims to evaluate the efficacy of a personalized multimodal intervention in lifestyle (diet counseling, physical activity, cognitive training, and social engagement) combined with the use of epigallocatechin gallate (EGCG) over 12 months, in slowing down cognitive decline and improving brain connectivity. The study population includes 200 individuals meeting SCD criteria and carrying the apolipoprotein E ε4 allele, who will be randomized into four treatment arms (multimodal intervention + EGCG/placebo, or lifestyle recommendations + EGCG/placebo). The primary efficacy outcome is change in the composite score for cognitive performance measured with the Alzheimer's Disease Cooperative Study Preclinical Alzheimer Cognitive Composite (ADCS‐PACC‐like) adding to the original version the Interference score from the Stroop Color and Word Test and the Five Digit Test. Secondary efficacy outcomes are (1) change in functional magnetic resonance imaging (fMRI) and structural neuronal connectivity (structural MRI) and (2) the safety assessment of the EGCG compound. This study is framed within the WW‐FINGERS consortium. DISCUSSION: The use of new technologies (i.e., mobile ecological momentary assessments [EMAs], activity tracker) in the PENSA study allows the collection of continuous data on lifestyle behaviors (diet and physical activity) and mood, enabling a personalized design as well as an intensive follow‐up of participants. These data will be used to give feedback to participants about their own performance along the intervention, promoting their involvement and adherence. The results of the study may aid researchers on the design of future clinical trials involving preventive lifestyle multicomponent interventions.
format Online
Article
Text
id pubmed-8012239
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80122392021-04-02 Prevention of cognitive decline in subjective cognitive decline APOE ε4 carriers after EGCG and a multimodal intervention (PENSA): Study design Forcano, Laura Fauria, Karine Soldevila‐Domenech, Natalia Minguillón, Carol Lorenzo, Thais Cuenca‐Royo, Aida Menezes‐Cabral, Sofia Pizarro, Nieves Boronat, Anna Molinuevo, José Luis de la Torre, Rafael Alzheimers Dement (N Y) Research Articles INTRODUCTION: Subjects exhibiting subjective cognitive decline (SCD) are at an increased risk for mild cognitive impairment and dementia. Given the delay between risk exposure and disease onset, SCD individuals are increasingly considered a good target population for cost‐effective lifestyle‐based Alzheimer's disease prevention trials. METHODS: The PENSA study is a randomized, double‐blind, controlled clinical trial that aims to evaluate the efficacy of a personalized multimodal intervention in lifestyle (diet counseling, physical activity, cognitive training, and social engagement) combined with the use of epigallocatechin gallate (EGCG) over 12 months, in slowing down cognitive decline and improving brain connectivity. The study population includes 200 individuals meeting SCD criteria and carrying the apolipoprotein E ε4 allele, who will be randomized into four treatment arms (multimodal intervention + EGCG/placebo, or lifestyle recommendations + EGCG/placebo). The primary efficacy outcome is change in the composite score for cognitive performance measured with the Alzheimer's Disease Cooperative Study Preclinical Alzheimer Cognitive Composite (ADCS‐PACC‐like) adding to the original version the Interference score from the Stroop Color and Word Test and the Five Digit Test. Secondary efficacy outcomes are (1) change in functional magnetic resonance imaging (fMRI) and structural neuronal connectivity (structural MRI) and (2) the safety assessment of the EGCG compound. This study is framed within the WW‐FINGERS consortium. DISCUSSION: The use of new technologies (i.e., mobile ecological momentary assessments [EMAs], activity tracker) in the PENSA study allows the collection of continuous data on lifestyle behaviors (diet and physical activity) and mood, enabling a personalized design as well as an intensive follow‐up of participants. These data will be used to give feedback to participants about their own performance along the intervention, promoting their involvement and adherence. The results of the study may aid researchers on the design of future clinical trials involving preventive lifestyle multicomponent interventions. John Wiley and Sons Inc. 2021-03-31 /pmc/articles/PMC8012239/ /pubmed/33816762 http://dx.doi.org/10.1002/trc2.12155 Text en © 2021 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Forcano, Laura
Fauria, Karine
Soldevila‐Domenech, Natalia
Minguillón, Carol
Lorenzo, Thais
Cuenca‐Royo, Aida
Menezes‐Cabral, Sofia
Pizarro, Nieves
Boronat, Anna
Molinuevo, José Luis
de la Torre, Rafael
Prevention of cognitive decline in subjective cognitive decline APOE ε4 carriers after EGCG and a multimodal intervention (PENSA): Study design
title Prevention of cognitive decline in subjective cognitive decline APOE ε4 carriers after EGCG and a multimodal intervention (PENSA): Study design
title_full Prevention of cognitive decline in subjective cognitive decline APOE ε4 carriers after EGCG and a multimodal intervention (PENSA): Study design
title_fullStr Prevention of cognitive decline in subjective cognitive decline APOE ε4 carriers after EGCG and a multimodal intervention (PENSA): Study design
title_full_unstemmed Prevention of cognitive decline in subjective cognitive decline APOE ε4 carriers after EGCG and a multimodal intervention (PENSA): Study design
title_short Prevention of cognitive decline in subjective cognitive decline APOE ε4 carriers after EGCG and a multimodal intervention (PENSA): Study design
title_sort prevention of cognitive decline in subjective cognitive decline apoe ε4 carriers after egcg and a multimodal intervention (pensa): study design
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012239/
https://www.ncbi.nlm.nih.gov/pubmed/33816762
http://dx.doi.org/10.1002/trc2.12155
work_keys_str_mv AT forcanolaura preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT fauriakarine preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT soldeviladomenechnatalia preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT minguilloncarol preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT lorenzothais preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT cuencaroyoaida preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT menezescabralsofia preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT pizarronieves preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT boronatanna preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT molinuevojoseluis preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT delatorrerafael preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign
AT preventionofcognitivedeclineinsubjectivecognitivedeclineapoee4carriersafteregcgandamultimodalinterventionpensastudydesign